BioInvent International (BINV) Q3 2024 earnings summary

Executive summary

• Positive clinical data reported for lead compounds BI-1206 (FcgammaRIIB, NHL), BI-1808 (TNF receptor 2, CTCL), and BT-001 (solid tumors), with notable responses in heavily pretreated patients and multiple value-inflection points expected in 2024–2025.

• Subcutaneous BI-1206 demonstrated improved activity and safety over IV, leading to a shift in ongoing and future studies.

• Six projects in clinical development and over ten development agreements as of September 2024, with expanded collaborations including AstraZeneca and MSD.

• Multiple programs advancing in clinical development, including triplet and combination therapies targeting solid tumors and lymphomas.

• New clinical trial collaborations, patent milestones, and presentations at ESMO and EHA 2024 highlight ongoing progress.

Financial highlights

• Q3 2024 net sales were SEK 12.8 million, down from SEK 26.8 million in Q3 2023; nine-month net sales were SEK 23.3 million, down from SEK 56.1 million in 2023.

• Operating costs increased to SEK 120 million in Q3 2024; nine-month operating loss was SEK -345.2 million.

• Net loss for Q3 2024 was SEK 97.2 million; nine-month loss totaled SEK 312.5 million.

• Liquid funds and investments at end of September 2024 amounted to SEK 979 million.

• Cash flow from operating activities for nine months was SEK -282.2 million.

Outlook and guidance

• Additional single agent phase 2 data for BI-1808 and first phase 1 data for BI-1910 expected by year-end 2024.

• Preliminary patient data for BI-1206 triplet combination anticipated by year-end 2024; further data readouts for BI-1808, BI-1206, and BI-1910 expected in 2025.

• Seven major data readouts anticipated in 2025 from four clinical assets.

• Management expects a busy year ahead with significant value-driving milestones and potential for strategic partnerships.